BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2115018)

  • 1. HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients.
    Mulder JW; Krijnen P; Goudsmit J; Schattenkerk JK; Reiss P; Lange JM
    Genitourin Med; 1990 Jun; 66(3):138-41. PubMed ID: 2115018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor HIV-1 p24 antigenaemia and course of infection in recipients Transfusion Safety Study Group.
    Busch MP; Donegan E; Stuart M; Mosley JW
    Lancet; 1990 Jun; 335(8701):1342. PubMed ID: 1971398
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictive markers of AIDS: a follow-up of lymphocyte subsets and HIV serology in a cohort of patients with lymphadenopathy.
    Böttiger B; Morfeldt-Månson L; Putkonen P; Nilsson B; Julander I; Biberfeld G
    Scand J Infect Dis; 1989; 21(5):507-14. PubMed ID: 2511625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.
    Williams IG; Gabriel G; Kelly G; Loveday C; Tedder RS; Weller IV
    AIDS; 1990 Sep; 4(9):909-12. PubMed ID: 2123627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
    Mulder JW; Lange JM; de Wolf F; Houweling JT; Bakker M; Coutinho RA; Goudsmit J
    Neth J Med; 1990 Aug; 37(1-2):4-10. PubMed ID: 2120599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of HIV-1 p24 antigenemia in African and North American populations and correlation with clinical status.
    Brown C; Kline R; Atibu L; Francis H; Ryder R; Quinn TC
    AIDS; 1991 Jan; 5(1):89-92. PubMed ID: 1905553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.
    Miles SA; Wang HJ; Cortes E; Carden J; Marcus S; Mitsuyasu RT
    Ann Intern Med; 1990 Apr; 112(8):582-9. PubMed ID: 2109563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4 lymphocyte counts and serum p24 antigen of no diagnostic value in monitoring HIV-infected patients with pulmonary symptoms.
    Orholm M; Nielsen TL; Nielsen JO; Lundgren JD
    AIDS; 1990 Feb; 4(2):163-6. PubMed ID: 1970256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune activation markers and AIDS prognosis.
    Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR
    AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive one-step enzyme immunoassay for HIV-1 p24 antigen in human blood specimens and cell culture supernatants.
    Kontio S
    J Immunol Methods; 1991 Jun; 139(2):257-63. PubMed ID: 1904466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient elevation of serum HIV antigen levels associated with intercurrent infection.
    Claydon EJ; Bennett J; Gor D; Forster SM
    AIDS; 1991 Jan; 5(1):113-4. PubMed ID: 1905552
    [No Abstract]   [Full Text] [Related]  

  • 12. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
    Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
    Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate markers for AIDS treatment.
    Jacobson M
    Nurs Times; 1991 May 29-Jun 4; 87(22):49. PubMed ID: 1675013
    [No Abstract]   [Full Text] [Related]  

  • 14. [Dynamics of the antibody response and p24 antigenemia in HIV-1 infected individuals in Czechoslovakia].
    Kopecká D; Brůcková M; Stanková M; Syrůcek L; Vojtĕchovský K; Petkov V
    Cesk Epidemiol Mikrobiol Imunol; 1990 Mar; 39(2):65-73. PubMed ID: 2142624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen's Hospital experience.
    Stambuk D; Hawkins D; Gazzard BG
    J Infect; 1989 Jan; 18 Suppl 1():41-51. PubMed ID: 2492585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
    Pedersen C; Cooper DA; Brun-Vézinet F; Doherty R; Skinhøj P; Pérol Y; Lüthy R; Leibowitch J; Habermehl KO; Varnier OE
    AIDS; 1992 Aug; 6(8):821-5. PubMed ID: 1418778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals.
    Nishanian P; Huskins KR; Stehn S; Detels R; Fahey JL
    J Infect Dis; 1990 Jul; 162(1):21-8. PubMed ID: 2113075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of p24 antigenemia, IgM, IgG antibodies to p24 and p41 and Ig virus isolation in rabbits experimentally infected with HIV-1.
    Filice G; Cereda PM; Orsolini P; Soldini L; Romero E; Rondanelli EG
    Microbiologica; 1990 Jul; 13(3):215-24. PubMed ID: 2125683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of quantitative levels of HIV p24 binding capacity in HIV infection.
    Croxson TS; Mathur-Wagh U; Handwerger S; Siroty WE; Kaminisky D; Reagan KJ; Yancovitz SR; Mildvan D
    AIDS Res Hum Retroviruses; 1990 Apr; 6(4):455-63. PubMed ID: 2111160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine.
    Berglund O; Engman K; Ehrnst A; Andersson J; Lidman K; Akerlund B; Sönnerborg A; Strannegård O
    J Infect Dis; 1991 Apr; 163(4):710-5. PubMed ID: 1672701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.